Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle

Quadrivalent influenza nanoparticle vaccines induce broad protection

(2021) Seyhan Boyoglu-Barnum et al.   NATURE

Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19

(2021) Brian J. Ward et al.   NATURE MEDICINE

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

(2020) Wanbo Tai et al.   Cellular & Molecular Immunology

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

(2020) Yan Wu et al.   SCIENCE

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

(2020) Katharine H. D. Crawford et al.   Viruses-Basel

A human monoclonal antibody blocking SARS-CoV-2 infection

(2020) Chunyan Wang et al.   Nature Communications

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

(2020) Christopher O. Barnes et al.   CELL

COVID-19, SARS and MERS: are they closely related?

(2020) N. Petrosillo et al.   CLINICAL MICROBIOLOGY AND INFECTION

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

(2020) Philip J. M. Brouwer et al.   SCIENCE

Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials

(2020) Brian J Ward et al.   LANCET

SARS-CoV-2 vaccines in development

(2020) Florian Krammer   NATURE

Nanovaccine: A novel approach in immunization

(2019) Seyed Mohammad Gheibi Hayat et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus

(2019) Jessica Marcandalli et al.   CELL

Vaccine Evolution and Its Application to Fight Modern Threats

(2019) Emanuele Andreano et al.   Frontiers in Immunology

RNA and Toll-Like Receptor 7 License the Generation of Superior Secondary Plasma Cells at Multiple Levels in a B Cell Intrinsic Fashion

(2019) Caroline C. Krueger et al.   Frontiers in Immunology

Engineering a Rugged Nanoscaffold to Enhance Plug-and-Display Vaccination

(2018) Theodora Ulli Jordanka Bruun et al.   ACS Nano

An Improved Tobacco Mosaic Virus (TMV)-Conjugated Multiantigen Subunit Vaccine Against Respiratory Tularemia

(2018) Ahd A. Mansour et al.   Frontiers in Microbiology

Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine

(2018) Fan Luo et al.   VIROLOGICA SINICA

Major findings and recent advances in virus–like particle (VLP)-based vaccines

(2017) Mona O. Mohsen et al.   SEMINARS IN IMMUNOLOGY

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

(2017) Rudragouda Channappanavar et al.   Seminars in Immunopathology

Synthetic plant virology for nanobiotechnology and nanomedicine

(2017) John F. C. Steele et al.   Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology

Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague

(2016) Paul M. Arnaboldi et al.   VACCINE

Development of a Multivalent Subunit Vaccine against Tularemia Using Tobacco Mosaic Virus (TMV) Based Delivery System

(2015) Sukalyani Banik et al.   PLoS One

Correction: Safety of the Malaria Vaccine Candidate, RTS,S/AS01E in 5 to 17 Month Old Kenyan and Tanzanian Children

(2014) John Lusingu et al.   PLoS One

Tobacco mosaic virus efficiently targets DC uptake, activation and antigen-specific T cell responses in vivo

(2014) Jan Ole Kemnade et al.   VACCINE

Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge

(2013) Jyothi K Mallajosyula et al.   Human Vaccines & Immunotherapeutics

Vaccine delivery using nanoparticles

(2013) Anthony E. Gregory et al.   Frontiers in Cellular and Infection Microbiology

Correction: Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

(2012) Chien-Te Tseng et al.   PLoS One

Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent Fc R Pathway

(2011) M. Jaume et al.   JOURNAL OF VIROLOGY

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial

(2011) Ally Olotu et al.   LANCET INFECTIOUS DISEASES

Polymeric human Fc-fusion proteins with modified effector functions

(2011) David N. A. Mekhaiel et al.   Scientific Reports

Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity

(2009) Lanying Du et al.   VIROLOGY

Genetically engineered Tobacco mosaic virus as nanoparticle vaccines

(2008) Alison A McCormick et al.   Expert Review of Vaccines